As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global

Execs See China Deal Structure, Valuation Evolving

 
• By Brian Yang

After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.

China growth
JUNSHI AND COHERUS SIGN PD-1 DEAL AS DEALMAKING STRONG FOR BIOTECH IN CHINA • Source: Shutterstock

More from China

More from Focus On Asia